15 October 2015 - The CADTH Canadian Drug Expert Committee has recommended that nintedanib esylate be listed for the treatment of patients with idiopathic pulmonary fibrosis if certain clinical criteria and condiitions are met.

For more details, go to: https://www.cadth.ca/sites/default/files/cdr/complete/SR0426_Ofev_Oct-19-15.pdf